Who are tPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrinolytic once daily, Recombinant Streptokinase, Recombinant Staphylokinase, Tenecteplase thrombolysis, TNK-tPA, Recombinant human tissue plasminogen activator.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tpa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

tPA — Competitive Intelligence Brief

tPA (tPA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrinolytic agent / Thrombolytic. Area: Cardiovascular.

marketed Fibrinolytic agent / Thrombolytic Plasminogen (converts to plasmin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

tPA (tPA) — Life Recovery Systems. tPA (tissue plasminogen activator) converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
tPA TARGET	tPA	Life Recovery Systems	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen (converts to plasmin)
Fibrinolytic once daily	Fibrinolytic once daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Recombinant Streptokinase	Recombinant Streptokinase	Beijing Chao Yang Hospital	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen
Recombinant Staphylokinase	Recombinant Staphylokinase	The First Affiliated Hospital with Nanjing Medical University	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen
Tenecteplase thrombolysis	Tenecteplase thrombolysis	Xuanwu Hospital, Beijing	marketed	Fibrinolytic agent / Thrombolytic	Fibrin; Plasminogen
TNK-tPA	TNK-tPA	Beijing Tiantan Hospital	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Recombinant human tissue plasminogen activator	Recombinant human tissue plasminogen activator	Angde Biotech Pharmaceutical Co., Ltd.	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrinolytic agent / Thrombolytic class)

All India Institute of Medical Sciences · 1 drug in this class
Angde Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Beijing Chao Yang Hospital · 1 drug in this class
Beijing Tiantan Hospital · 1 drug in this class
Life Recovery Systems · 1 drug in this class
Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
Thrombolex, Inc. · 1 drug in this class
Tianjin Huanhu Hospital · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tPA — Competitive Intelligence Brief. https://druglandscape.com/ci/tpa. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab